Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Nov 16;60(2):735-43.
doi: 10.1128/AAC.01370-15. Print 2016 Feb.

Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum

Affiliations

Selective Inactivity of Pyrazinamide against Tuberculosis in C3HeB/FeJ Mice Is Best Explained by Neutral pH of Caseum

Jean-Philippe Lanoix et al. Antimicrob Agents Chemother. .

Abstract

Pyrazinamide (PZA) is one of only two sterilizing drugs in the first-line antituberculosis regimen. Its activity is strongly pH dependent; the MIC changes by several orders of magnitude over a range of pH values that may be encountered in various in vivo compartments. We recently reported selective inactivity of PZA in a subset of C3HeB/FeJ mice with large caseous lung lesions. In the present study, we evaluated whether such inactivity was explained by poor penetration of PZA into such lesions or selection of drug-resistant mutants. Despite demonstrating similar dose-proportional PZA exposures in plasma, epithelial lining fluid, and lung lesions, no dose response was observed in a subset of C3HeB/FeJ mice with the highest CFU burden. Although PZA-resistant mutants eventually replaced the susceptible bacilli in BALB/c mice and in C3HeB/FeJ mice with low total CFU burdens, they never exceeded 1% of the total population in nonresponding C3HeB/FeJ mice. The selective inactivity of PZA in large caseous lesions of C3HeB/FeJ mice is best explained by the neutral pH of liquefying caseum.

PubMed Disclaimer

Figures

FIG 1
FIG 1
Dose-ranging PZA concentration-time profiles in uninfected C3HeB/FeJ mice in plasma. The data are plotted as means and SD.
FIG 2
FIG 2
Dose-ranging PZA concentration-time profiles in infected C3HeB/FeJ mice in plasma (solid symbols) and lesions (open symbols) for doses of 150 and 450 mg/kg BID. Panels A and B represent 2 different sets of experiments. The data are plotted as means and SD.
FIG 3
FIG 3
Dose-response profiles in C3HeB/FeJ mice (A) and BALB/c mice (B) after 3 weeks (blue) and 8 weeks (red) of treatment (W3 and W8, respectively). C3HeB/FeJ mice excluded from the curve fit (outliers) are circled.
FIG 4
FIG 4
Total CFU counts (solid symbols) and PZA-resistant CFU counts (open symbols) in C3HeB/FeJ mice treated with increasing PZA doses. Each symbol shape represents an individual mouse in its dose group. Blue, CFU counts from mice considered to fit the dose-response curve shown in the inset; red, CFU counts from mice considered nonresponsive to the dose increase; solid symbols, total CFU counts determined on drug-free medium for each individual mouse; open symbols, resistant-CFU counts determined on PZA-containing plates for the same mouse.

Similar articles

Cited by

References

    1. British Thoracic and Tuberculosis Association. 1976. Short-course chemotherapy in pulmonary tuberculosis. A controlled trial by the British Thoracic and Tuberculosis Association. Lancet ii:1102–1104. - PubMed
    1. British Thoracic Society. 1984. A controlled trial of 6 months' chemotherapy in pulmonary tuberculosis. Final report: results during the 36 months after the end of chemotherapy and beyond. Br J Dis Chest 78:330–336. - PubMed
    1. Zhang Y, Mitchison D. 2003. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 7:6–21. - PubMed
    1. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, Wang H, Zhang W, Zhang Y. 2011. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science 333:1630–1632. doi:10.1126/science.1208813. - DOI - PMC - PubMed
    1. Zhang Y, Permar S, Sun Z. 2002. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 51:42–49. doi:10.1099/0022-1317-51-1-42. - DOI - PubMed

Publication types